Clinical application of voriconazole in pediatric patients: a systematic review

被引：4
作者：
Hu, Lin [1 ,2 ]
Huang, Juanjuan [1 ,2 ]
Li, Yanfei [1 ,2 ]
He, Gefei [1 ,2 ]
机构：
[1] Cent South Univ, Affiliated Changsha Hosp, Xiangya Sch Med, Dept Pharm, Changsha, Hunan, Peoples R China
[2] First Hosp Changsha, Dept Pharm, Changsha, Hunan, Peoples R China
来源：
ITALIAN JOURNAL OF PEDIATRICS | 2024年 / 50卷 / 01期
关键词：
Voriconazole; Pediatric patients; Plasma trough concentrations; Factors; Optimal dose; POPULATION PHARMACOKINETIC ANALYSIS; INFECTIOUS-DISEASES SOCIETY; INVASIVE FUNGAL-INFECTION; PLASMA-CONCENTRATIONS; PRACTICE GUIDELINES; INTRAVENOUS VORICONAZOLE; CHILDREN; CYP2C19; IMPLEMENTATION; POLYMORPHISMS;
D O I：
10.1186/s13052-024-01684-z
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
The purpose of this study was to review the literature on the clinical use of voriconazole (VRC) in pediatric patients. MEDLINE, Embase, PubMed, Web of Science, and Cochrane Library were searched from January 1, 2000, to August 15, 2023 for relevant clinical studies on VRC use in pediatric patients. Data were collected based on inclusion and exclusion criteria, and a systematic review was performed on recent research related to the use of VRC in pediatric patients. This systematic review included a total of 35 observational studies among which there were 16 studies investigating factors influencing VRC plasma trough concentrations (Ctrough) in pediatric patients, 14 studies exploring VRC maintenance doses required to achieve target range of Ctrough, and 11 studies focusing on population pharmacokinetic (PPK) research of VRC in pediatric patients. Our study found that the Ctrough of VRC were influenced by both genetic and non-genetic factors. The optimal dosing of VRC was correlated with age in pediatric patients, and younger children usually required higher VRC doses to achieve target Ctrough compared to older children. Establishing a PPK model for VRC can assist in achieving more precise individualized dosing in children.
引用
收藏
页数：12
相关论文
共 61 条
[1]   Use of the STROBE Checklist to Evaluate the Reporting Quality of Observational Research in Obstetrics [J].
Adams, April D. ;
Benner, Rebecca S. ;
Riggs, Thomas W. ;
Chescheir, Nancy C. .
OBSTETRICS AND GYNECOLOGY, 2018, 132 (02) :507-512
[2]   Regulation of drug-metabolizing enzymes and transporters in inflammation [J].
Aitken, AE ;
Richardson, TA ;
Morgan, ET .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2006, 46 :123-149
[3]   Pharmacogenetic of voriconazole antifungal agent in pediatric patients [J].
Allegra, Sarah ;
Fatiguso, Giovanna ;
De Francia, Silvia ;
Pirro, Elisa ;
Carcieri, Chiara ;
Cusato, Jessica ;
De Nicolo, Amedeo ;
Avataneo, Valeria ;
Di Perri, Giovanni ;
D'Avolio, Antonio .
PHARMACOGENOMICS, 2018, 19 (11) :913-925
[4]   Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children [J].
Allegra, Sarah ;
Fatiguso, Giovanna ;
De Francia, Silvia ;
Favata, Fabio ;
Pirro, Elisa ;
Carcieri, Chiara ;
De Nicolo, Amedeo ;
Cusato, Jessica ;
Di Perri, Giovanni ;
D'Avolio, Antonio .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (01) :197-203
[5]  
[Anonymous], FDA drug label information of voriconazole
[6]   Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology [J].
Ashbee, H. Ruth ;
Barnes, Rosemary A. ;
Johnson, Elizabeth M. ;
Richardson, Malcolm D. ;
Gorton, Rebecca ;
Hope, William W. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (05) :1162-1176
[7]   Highly Variable Plasma Concentrations of Voriconazole in Pediatric Hematopoietic Stem Cell Transplantation Patients [J].
Bartelink, Imke H. ;
Wolfs, Tom ;
Jonker, Martine ;
de Waal, Marjolein ;
Egberts, Toine C. G. ;
Ververs, Tessa T. ;
Boelens, Jaap J. ;
Bierings, Marc .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (01) :235-240
[8]   Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre [J].
Boast, Alison ;
Curtis, Nigel ;
Cranswick, Noel ;
Gwee, Amanda .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (07) :2031-2036
[9]   Combined Effect of CYP2C19 Genetic Polymorphisms and C-Reactive Protein on Voriconazole Exposure and Dosing in Immunocompromised Children [J].
Chen, Juan ;
Wu, Ying ;
He, Yuelin ;
Feng, Xiaoqin ;
Ren, Yuqiong ;
Liu, Shiting .
FRONTIERS IN PEDIATRICS, 2022, 10
[10]   Individualized Medication of Voriconazole: A Practice Guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society [J].
Chen, Ken ;
Zhang, Xianglin ;
Ke, Xiaoyan ;
Du, Guanhua ;
Yang, Kehu ;
Zhai, Suodi ;
An, Youzhong ;
Chen, Yaolong ;
Dong, Yalin ;
Guo, Ruichen ;
He, Bei ;
Jiang, Bin ;
Li, Huande ;
Lv, Yuan ;
Ma, Xiaojun ;
Miao, Liyan ;
Wang, Jianmin ;
Wang, Rui ;
Wu, Jiuhong ;
Yang, Linhua ;
Zhan, Siyan ;
Zhang, Jing ;
Zhao, Limei ;
Zhao, Rongsheng ;
Zhao, Zhigang ;
Zhou, Guohua ;
Guo, Yimeng ;
Jin, Haiying ;
Li, Taoyuan ;
Li, Xiaofei ;
Liang, Shuyao ;
Liu, Fang ;
Liu, Wei ;
Liu, Yuanyuan ;
Song, Zaiwei ;
Tang, Huilin ;
Wang, Tiansheng ;
Xu, Xiaohan ;
Yang, Huixia ;
Yi, Zhanmiao .
THERAPEUTIC DRUG MONITORING, 2018, 40 (06) :663-674
1234567